InvestSMART

Mesoblast Limited (ASX: MSB) - ETF Exposure

Current share price for MSB : $1.760 0.035 (1.95%)+

Mesoblast Limited (MSB) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a Company that is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in reduction of the damaging inflammatory process.

MSB General Information +

ASX Code MSB
Website http://www.mesoblast.com
Industry/Sector Biotechnology
Market Cap ($M) 2,290
MSB Share Price $1.760
Day High $1.823
Day Low $1.760
Last Close $1.795
MSB Share Price Movement $0.03 ( 1.95% )
Prices as at 16:40, 18 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to MSB

As a significant Australian company by market capitalisation, MSB is held across 21 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when MSB moves, funds like ISO, SSO, FAIR, VSO and OZXX that hold it can move with it.

For more concentrated exposure, ETFs such as ISO (iShares S&P/ASX Small Ordinaries ETF Index Fund) allocate about 0.6% to MSB , while the average exposure across all 21 ETFs that hold it is around 0.2% .

Top ETF holdings

Last updated: ETF data and holdings as at 17 November 2026

Own MSB directly or through an ETF?

How does holding Mesoblast Limited (MSB) shares directly compare to ETFs that include it?

MSB Direct
ISO
ASX
SSO
ASX
FAIR
ASX
VSO
ASX
OZXX
ASX
Holdings 1 company 220 holdings 220 holdings 95 holdings 204 holdings 109 holdings
MSB Weight 100% 0.6% 0.6% 0.5% 0.3% 0.2%
Diversification Single Stock Broad Broad Broad Broad Broad
Annual Cost Brokerage only 0.55% p.a. 0.5% p.a. 0.49% p.a. 0.3% p.a. 0.25% p.a.
Approx. Yield 0% 4.69% 9.91% 2.97% 4.97% 5.43%
Star Ratings - starstarstar starstar starstarstarstar starstarstarstar starstarstar

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not MSB's direct yield. Annual cost uses each ETF's MER.

MSB Exposure on $10,000 investment

How a $10,000 investment in Mesoblast Limited (MSB) one week ago compares with ETFs that hold it.

Security Investment type Current price 7-day price movement Dollar change Value today
Mesoblast Limited (MSB) Direct share $1.760 -15.38% -$1,538 $8,462
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) Equity - Australia Small/Mid Cap $4.660 -5.48% -$548 $9,452
State Street SPDR S&P/ASX Small Ordinaries ETF (SSO) Equity - Australia Small/Mid Cap $13.530 -4.72% -$472 $9,528
BetaShares Australian Sustainability Leaders ETF (FAIR) Equity - Australia Strategy $19.480 -0.81% -$81 $9,919
Vanguard MSCI Australian Small Companies Index ETF (VSO) Equity - Australia Small/Mid Cap $70.290 -4.73% -$473 $9,527
Global X Australia ex Financials & Resources ETF (OZXX) Equity - Australia Sectors $10.360 -1.52% -$152 $9,848

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Mesoblast Limited (MSB) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Mesoblast Limited (MSB) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Mesoblast Limited (MSB) price-sensitive announcements

MSB - Quarterly Activities/Appendix 4C Cash Flow Report
Mesoblast Limited’s Appendix 4C and quarterly activities report for the first quarter of F
Mesoblast Limited (MSB)
29 Oct 2026 | 9:54 AM
MSB - MSB Reports Increased Revenue and Improved Operating Spend
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) announced that in the first quarter of fiscal y
Mesoblast Limited (MSB)
16 Oct 2026 | 10:15 AM
MSB - FDA Approves New Potency Assay for Commercial Ryoncil
Mesoblast Limited announced that the US Food and Drug Administration approved a new potenc
Mesoblast Limited (MSB)
24 Sep 2026 | 9:52 AM
MSB - MSB Annual Financial Results and Operational Update
Mesoblast Limited’s FY2026 annual financial results and operational update for the year en
Mesoblast Limited (MSB)
27 Aug 2026 | 8:39 AM

Mesoblast Limited (MSB) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Mesoblast Limited (MSB)
ORDINARY FULLY PAID
Health Care $2,290 Mesoblast Showcased at ASX Investor Day 16 Nov 2026 9:48AM $1.930 $1.760 fallen by 8.81%
Mesoblast Limited (MSB)
ORDINARY FULLY PAID
Health Care $2,290 CEO Presentation ASX Investor Day 16 Nov 2026 9:42AM $1.930 $1.760 fallen by 8.81%
Mesoblast Limited (MSB)
ORDINARY FULLY PAID
Health Care $2,290 Initial Director's Interest Notice 13 Nov 2026 5:06PM $1.930 $1.760 fallen by 8.81%
Mesoblast Limited (MSB)
ORDINARY FULLY PAID
Health Care $2,290 Results of Meeting 10 Nov 2026 5:14PM $2.080 $1.760 fallen by 15.38%
Mesoblast Limited (MSB)
ORDINARY FULLY PAID
Health Care $2,290 CEO Presentation to 2026 Annual General Meeting 10 Nov 2026 9:07AM $2.040 $1.760 fallen by 13.73%
Mesoblast Limited (MSB)
ORDINARY FULLY PAID
Health Care $2,290 Mesoblast Chair Message to 2026 AGM 10 Nov 2026 8:59AM $2.040 $1.760 fallen by 13.73%

MSB Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2028F C2 $0.20 -106.50% 815.90 0.00 0.00% 0.0%
2027F C2 -$3.40 -50.20% 0.00 0.00 0.00% 0.0%
2026A -$87.79 -$6.80 -45.00% 0.00 0.00 0.00% 0.0%

MSB Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2026 A 2027 F 2028 F 2026 A 2027 F 2028 F 2026 A 2027 F 2028 F
CSL Limited (CSL) $97,186M 0.7309 -0.4374 0.0602 12.5465 22.3000 21.0343 2.10% 2.11% 2.18%
Clinuvel Pharmaceuticals Limited (CUV) $383M -0.0696 -0.0719 0.0242 11.3623 12.2419 11.9528 0.66% 0.66% 0.66%
Mesoblast Limited (MSB) $2,453M -0.4501 0.0000 0.0000 0.0000 0.0000 856.8182 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $1,763M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $4,557M -1.3893 0.0000 -0.5229 0.0000 156.9754 328.9926 0.00% 0.00% 0.00%

MSB Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 2.81 0.00
Market 0.64 15.60 1.43 1.28
Sector 0.74 33.00 2.24 2.76

MSB Directors

Name Position Start Date
Professor Silviu Itescu Chief Executive Officer, Executive Director 8 Jun 2004
Ms Jane Catherine Bell Non-Executive Director 18 Aug 2022
Ms Lynette Elizabeth Cobley Non-Executive Director 29 Apr 2025
Dr Gregory George Non-Executive Director 24 Feb 2025
Mr Jon Voigtman Non-Executive Director 10 Nov 2026
Mr Philip J. Facchina Non-Executive Director, Non-Executive Chairman 29 Mar 2021

Mesoblast Limited (MSB) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
17 Jul 2026 ITESCU, Silviu Exercise Options 1,885,334 $1.450 $2,733,734.000
17 Jul 2026 ITESCU, Silviu Buy Direct Shares 1,885,334 $1.450 $2,733,734.000
10 Apr 2026 GEORGE, Gregory Buy Indirect Shares 7,210,962 $1.445 $10,418,591.090

See all changes in directors' interest & trades for Mesoblast Limited (MSB) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

MSB Management

Name Position
Niva Sivakumar Joint Company Secretary
Paul Hughes Joint Company Secretary

MSB Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Mesoblast Limited (MSB). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
286,002,539 (22.04%) Gregory George Patching
80,844,262 (6.23%) Silviu Itescu
65,660,115 (5.06%) State Street Corporation and its subsidiaries
64,171,900 (4.95%) William Gueck

MSB Calendar of Events

Date Event
11 October 2027 Report (Annual)
26 August 2027 Report (Prelim)
26 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.